Kowa Company Limited

Mitsubishi Denki Kabushiki Kaisha

Optec D.d. Melco Laboratory Co., Ltd.

Optec Dai-ichi Denko Co., Ltd.

Japan Display Inc.

Ajinomoto Co., Ltd.

Namco Limited

Tomy Company, Ltd.

Sato Pharmaceutical Co., Ltd.

Kabushiki Kaisha Toshiba

Ihi Corporation

Toshiba Matsushita Display Technology Co., Ltd.

Manco, Inc.

Optec D.d. Meico Laboratory Co., Ltd.

Optec Dai-ichi Denko., Ltd.

Seiichi Sato

Hiromichi Shigyo

Yoshinori Kyotani

Hiroyuki Ishiwata

Soichi Oda

Mototsugu Kabeya

Manabu Shibasaki

Makoto Suda

Yasumi Uchida

Masami Shiratsuchi

Takahiro Kitamura

Hiroshi Nakao

Shunji Takemura

Takao Nagoya

Tomio Ohta

Yukio Hattori

Tadaaki Ohgiya

Atsushi Ueda

Kazuo Yamaguchi

Masami Matsumura

Tomoyuki Koshi

Kiyoshi Kawamura

Kyoko Yasuoka

Noboru Shimizu

Junko Totsuka

Yoshi Kurosawa

Hideo Yoshizaki

Junya Tagashira

Koji Yamamoto

Toru Miura

Hajime Yamada

Kazuhiro Onogi

Masahiko Nagakura

Yoshio Takahashi

Hisashi Kunieda

Fumie Futaki

Toshihiro Akashi

Shigeichi Nakamura

Ryohei Sekimoto

Rie Ishida

Hitomi Aoki

Naotoshi Sawada

Masahiro Tamura

Hideyuki Takahashi

Tetsuya Ishikawa

Masato Nakamura

Takashi Yamaguchi

Yoshinori Ito

Tetsuya Iizuka

Kimiyuki Shibuya

Masakatsu Kitani

Nobuko Fukuoka

Yuzuru Eto

Makoto Inoue

Tsutomu Toma

Reiko Yasuda

Sohei Tanabe

Yoshiharu Miyake

Toshiaki Watanabe

Hiroyuki Kimura

Takuya Hara

Koichi Ishii

Takahiro Ito

Hirokazu Morimoto

Toshiaki Oda

Akihiko Saitoh

Yasuyuki Hanazawa

Hideo Morita

Hiroyuki Yagi

Tsutomu Murakami

Naoyuki Fukuchi

Yoshitaka Yamada

Takeshi Doi

Morikazu Kito

Masao Ohkuchi

Toru Ogawa

Yasuko Jojima

Katsumi Kawamine

Toshimi Mizoguchi

Naohiro Miyamura

Yukitsugu Ono

Takaomi Inada

Akiko Tanaka

Koichiro Watanabe

Toshiharu Arai

Masanori Ashikawa

Gen Watanabe

Natsuyo Kumai

Yukihiro Okuno

Junko Shinozaki

Takatoshi Ozawa

Yuichiro Tabunoki

Takashi Miyaki

Yumiko Suzuki

Takaho Tajima

Fumitaka Imamura

Satoru Hagihara

Akiyasu Kouketsu

A substance is described which is capable of imparting a kokumi, which shows a more excellent kokumi-imparting effect, in particular, the initial taste-imparting type of kokumi-imparting effect, which is excellent in the stability and which can easily be produced at a low cost. Additionally, a kokumi-imparting composition which includes a substance as well as a kokumi-imparting agent including the substance and other substances possessing the CaSR agonist activities in combination. More particularly, the present invention herein provides a kokumi-imparting composition consisting of &#x3b3;-Glu-Abu (L-&#x3b3;-glutamyl-L-2-amino-butyric acid) and a complex kokumi-imparting agent which includes the foregoing substance and another substance having a CaSR agonist activity, in combination.

Use of peptides for imparting kokumi

According to one embodiment, provide is a liquid crystal display device that suppresses potential change of a common electrode caused by potential change of a signal line. An electrode part is provided on an array substrate so as to surround a display region. A signal line is provided on the array substrate so as to be located in the display region. A passivation film is provided on the array substrate so as to cover at least the signal line and the electrode part. A one-side opening part is provided continuously along an edge part of the display region on the passivation film so that the electrode part is disposed. The common electrode is provided on the array substrate so that a part of the common electrode is located at the one-side opening part and another part of the common electrode is located facing the signal line on the passivation film.

Liquid crystal display device

According to one embodiment, there is a third column of third color (Blue) pixels and fourth (White) color pixels arranged alternately. The first set of a first (Red), a second (Green) and a third (Blue) color pixels along the first direction, and the second set of a first (Red), a second (Green) and a fourth (White) color pixels along the first direction are each defined as a composite color unit pixel. In the composite color unit pixels located at the first or second one along the first direction from composite color unit pixels to which color pixels of the third columns belongs, a connection pattern is designed that the pixels of the third columns are connected to the odd-numbered gate lines and the even-numbered gate lines, alternately, along the first direction.

Liquid crystal display

According to one embodiment, three columns of a first and second columns of first and second color pixels, and a third column of third and fourth color pixels arranged alternately, are repeatedly provided along a first direction. The first set of a first, a second and a third color pixels along the first direction, and the second set of a first, a second and a fourth color pixels along the first direction are each defined as a composite color unit pixel. Pixel signals are supplied to the pixels of the third columns in a pattern that polarities of the pixel signals of the pixels of the third columns along the first direction are . . . , +, +, &#x2212;, &#x2212;, +, +, &#x2212;, &#x2212;, +, +, &#x2212;, &#x2212;, . . . .

Driving method of a display device, and a display device

The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPAR&#x3b3; activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C&#x2014;Ror a nitrogen atom; Rrepresents an alkyl group; Rrepresents an alkyl group or a cycloalkyl group; and R, R, and Reach independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar. 

Phenylpyridine derivative and drug containing same

Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPAR&#x3b3;-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C&#x2014;Ror a nitrogen atom; Rrepresents a Calkyl group; Rrepresents a Calkyl group or a Ccycloalkyl group; and R, R, Rindependently represent a hydrogen atom, a halogen atom, a Calkyl group, a halo-Calkyl group, or a Calkoxy group which may have a substituent), a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition containing the compound, the salt or the solvate.

Phenylpyridine derivative and medicinal agent comprising same

Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPAR&#x3b3; activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; Rand Rindependently represent a Calkyl group; and each of Rto Ris absent or represents H, a halogen atom, OH, NO, a halo-Calkyl group, a (substituted) Calkoxy group, a (substituted) Ccycloalkyloxy group, or a 5- to 10-membered heteroaryl group.]

Compound having 3-heteroarylpyrimidin-4-(3H)-one structure and pharmaceutical preparation containing same

To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sj&#xf6;gren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.

Pyridine-3-carboxyamide derivative

The present invention provides a variety of compounds having a CaSR agonist activity which possesses a superior kokumi-imparting function, and more particularly provides a kokumi-imparting composition, which contains the foregoing compound, and/or another substance having a CaSR agonist activity, in combination. The present invention also provides a kokumi-imparting composition which includes a lanthionine derivative and/or another substance having a CaSR agonist activity.

Lanthionine derivatives

A preserving apparatus for preserving welded joint portionsby deposit welding on the inner surface of the welded joint portions, in which a nozzleand a pipesupported under water are joined, the apparatus having: a seal memberthat is disposed in front and behind the welded joint portionsto be deposit welded within the nozzleand pipe, and serves to demarcate and form a closed operation area A within the nozzleand pipe; water drainage meansfor draining the inside of the operation area A demarcated and formed by the seal memberand obtaining a gas atmosphere therein; and welding meansfor deposit welding on the inner surface of the welded joint portionswithin the operation area A in which the gas atmosphere has been created.

Preserving apparatus for welded joint portion and preserving method therefor

The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.

Tetrahydroisoquinoline compound

Eye drop container

A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.

Substance with antithrombotic activity and method for detecting glycokallidin

In order to reduce the number of processes for manufacturing spacers and to prevent quality degradation resulting from a cell gap, a spacerin a semi-transmission areais formed outside of a region of a bump layerB. Thus, it is made possible to manufacture the spacer in the transmission regionand the spacer outside of the region of the bump layer in the same process. Accordingly, the number of processes can be reduced. Moreover, it is made possible to determine the cell gap in the semi-transmission areaby a single element of a spacer. Accordingly, precision degradation of the cell gap, which results from the bump layer, can be prevented, and high display quality can be obtained.

LCD device having a semi-transmission area with bump layer in a reflective portion thereof and a transmission portion having a transparent electrode with spacer disposed thereon

The present invention is directed to a compound represented by formula (1): (wherein Rrepresents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and each of Rand Rrepresents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or Rand Rform, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent) and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-&#x3b1;) production inhibitory effect and improved absorption upon oral administration.

Benzofuran derivative

Growing community of inventors

Tokyo, Japan

Seiichi Sato